Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin’s Lymphoma
Study Information
Alliance Study ID: NCCTG-N9981
NCT Study ID (ClinicalTrials.gov): NCT00005601
Disease or Cancer Type: Lymphoma
Alliance Study Chair: Thomas E. Witzig, MD
Status: COMPLETED
Study Description
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining combination chemotherapy with monoclonal antibody therapy may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus rituximab in treating patients who have relapsed non-Hodgkin’s lymphoma.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information